20(S)-Ginsenoside Rg3 (Synonyms: 20(S)-Propanaxadiol) |
| Catalog No.GN10799 |
20(S)-Ginsenoside Rg3 is a rare ginsenoside extracted from ginseng (Na+: IC50 = 32.2±4.5μM; hKv1.4: IC50 = 32.6±2.2μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14197-60-5
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
20(S)-Ginsenoside Rg3 is a rare ginsenoside extracted from ginseng (Na+: IC50 = 32.2±4.5μM; hKv1.4: IC50 = 32.6±2.2μM) [1-2]. 20(S)-Ginsenoside Rg3 inhibits Aβ aggregation, NF-κB activity, and COX-2 expression, exerting neuroprotective and anti-inflammatory effects [3]. 20(S)-Ginsenoside Rg3 is often used in adjuvant anticancer therapy [4].
In human umbilical vein endothelial cells, 20(S)-Ginsenoside Rg3 (1, 5, 10μg/mL; 36h) protects endothelial cells from serum-deprived apoptosis [5]. In HIT-T15 cells, 20(S)-Ginsenoside Rg3 (2, 4, 8, 16μM; 1h) at the concentration range between 2 and 8μM augmented a glucose-stimulated insulin secretion in a concentration dependent manner [6]. In HT29 cells, 20(S)-Ginsenoside Rg3 (25, 50, 100, 200, 400, 600μM; 24h, 48h) reduced proliferation in a dose-dependent manner [7].
In institute of cancer research mice, 20(S)-Ginsenoside Rg3 (12.5, 25mg/kg; po; single oral dose) reduces blood sugar levels by stimulating insulin secretion [6]. In H22-bearing mice model, the growth of H22 transplanted tumors was inhibited when treated with 20(S)-Ginsenoside Rg3 (3mg/kg; ip;10d), and the cellular immunity of H22-bearing mice was remarkably enhanced after 20(S)-Ginsenoside Rg3 treatment [8].
References:
[1]. Kim JH, Hong YH, Lee JH, et al. A role for the carbohydrate portion of ginsenoside Rg3 in Na+ channel inhibition. Molecules and Cells. 2005 Feb 1; 19(1): 137-142.
[2]. Lee JH, Lee BH, Choi SH, et al. Ginsenoside Rg3 inhibits human Kv1.4 channel currents by interacting with the Lys531 residue. Mol Pharmacol. 2008 Mar; 73(3): 619-626.
[3]. Lee IS, Uh I, Kim KS, et al. Anti‐inflammatory effects of ginsenoside Rg3 via NF‐κB pathway in A549 cells and human asthmatic lung tissue. Journal of Immunology Research. 2016; 2016(1): 7521601.
[4]. Mochizuki M, Yoo Y, MATsUzAwA K, et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20 (R)-and 20 (S)-ginsenoside-Rg3, of red ginseng. Biological and Pharmaceutical Bulletin. 1995 Sep 15; 18(9): 1197-1202.
[5]. Min JK, Kim JH, Cho YL, et al. 20 (S)-Ginsenoside Rg3 prevents endothelial cell apoptosis via inhibition of a mitochondrial caspase pathway. Biochemical and Biophysical Research Communications. 2006 Oct 27; 349(3): 987-994.
[6]. Park MW, Ha J, Chung SH. 20 (S)-ginsenoside Rg3 enhances glucose-stimulated insulin secretion and activates AMPK. Biological and Pharmaceutical Bulletin. 2008 Apr 1; 31(4): 748-751.
[7]. Lee SY, Kim GT, Roh SH, et al. Proteomic analysis of the anti-cancer effect of 20 S-ginsenoside Rg3 in human colon cancer cell lines. Bioscience, biotechnology, and biochemistry. 2009 Apr 23; 73(4): 811-816.
[8]. Wu R, Ru Q, Chen L, et al. Stereospecificity of Ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22‐bearing mice. Journal of Food Science. 2014 Jul; 79(7): H1430- H1435.
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Preparation Method | HUVECs (1×105 cells/well) were plated onto six well plates in 1ml M199 containing 20% fetal bovine serum. Next day, the cells were switched to serum-free M199 with or without 20% fetal bovine serum and 20(S)-Ginsenoside Rg3. After 36h, cell viability was assessed by trypan blue exclusion. Counts were performed on triplicate wells. |
Reaction Conditions | 1, 5, 10μg/mL; 36h |
Applications | 20(S)-Ginsenoside Rg3 protects endothelial cells from serum-deprived apoptosis. |
| Animal experiment [2]: | |
Animal models | Institute of cancer research (ICR) mice |
Preparation Method | Oral glucose tolerance test (OGTT). The ICR mice were fasted for 12h prior to the experiment, and 20(S)-Ginsenoside Rg3 (12.5, 25mg/kg) was administered orally 30min prior to glucose challenge. Glucose (1.5g/kg) was orally administered at 0min, and the blood was withdrawn from the orbital venous plexus at 0, 30, 60 and 120min after glucose administration. Plasma glucose and insulin levels were determined by the glucose oxidase method and mouse insulin ELISA kit, respectively. |
Dosage form | 12.5, 25mg/kg; po; single oral dose |
Applications | 20(S)-Ginsenoside Rg3 reduces blood sugar levels by stimulating insulin secretion. |
References: | |
| Cas No. | 14197-60-5 | SDF | |
| Synonyms | 20(S)-Propanaxadiol | ||
| Chemical Name | (2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-dihydroxy-2-(((3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran- | ||
| Canonical SMILES | O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O[C@H]2[C@H](O[C@@H]3C(C)(C)[C@@](CC[C@]([C@@](CC[C@@H]4[C@](C)(CC/C=C(C)\C)O)(C)[C@]4([H])[C@H](O)C5)(C)[C@@]65[H])([H])[C@]6(C)CC3)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H]1O | ||
| Formula | C42H72O13 | M.Wt | 785.01 |
| Solubility | DMF: 10 mg/ml,DMSO: 10 mg/ml,Ethanol: 20 mg/ml,Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml | Storage | -20℃ |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2739 mL | 6.3693 mL | 12.7387 mL |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *